Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 60,400 shares, an increase of 153.8% from the November 30th total of 23,800 shares. Based on an average daily trading volume, of 966,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the company's shares are sold short.
Scopus BioPharma Stock Performance
NASDAQ SCPS remained flat at $0.11 on Wednesday. The company's stock had a trading volume of 228,118 shares, compared to its average volume of 375,267. The company's fifty day moving average price is $0.22 and its 200 day moving average price is $0.31. Scopus BioPharma has a 12-month low of $0.06 and a 12-month high of $1.79.
Get Scopus BioPharma alerts:Institutional Trading of Scopus BioPharma
An institutional investor recently raised its position in Scopus BioPharma stock. Renaissance Technologies LLC boosted its stake in shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,523 shares of the company's stock after buying an additional 91,623 shares during the period. Renaissance Technologies LLC owned about 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.16% of the company's stock.
Scopus BioPharma Company Profile
(Get Rating)Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
See Also
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.